Clinical Trial Update: 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 8 continuous vs 8 intermittent cycles in first/second line treatment for HER2-negative metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Borstkanker Onderzoek Groep | Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer | Phase 3 | Status: COMPLETED